Compare Stocks: IONS, GMAB, ROIV, and UTHR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GMAB Genmab A/S	$57.06 +1.0%	$37.12	$23.62 ▼ $59.97	$35.25B	0.81	6.44 million shs	8.65 million shs
IONS Ionis Pharmaceuticals	$43.52 -2.0%	$49.02	$42.08 ▼ $86.74	$7.38B	0.38	2.73 million shs	1.52 million shs
ROIV Roivant Sciences	$36.91 -1.6%	$36.65	$19.30 ▼ $42.50	$27.10B	1.1	6.66 million shs	4.57 million shs
UTHR United Therapeutics	$598.72 +0.9%	$527.10	$430.02 ▼ $609.99	$25.46B	0.49	720,784 shs	502,797 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GMAB Genmab A/S	+1.01%	+30.30%	+59.97%	+97.64%	+97.10%
IONS Ionis Pharmaceuticals	-1.96%	+1.37%	-2.53%	-15.94%	-39.45%
ROIV Roivant Sciences	-1.63%	+1.15%	+0.93%	+8.85%	+96.75%
UTHR United Therapeutics	+0.87%	+1.91%	+10.49%	+15.65%	+31.49%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GMAB Genmab A/S	$57.06 +1.0%	$37.12	$23.62 ▼ $59.97	$35.25B	0.81	6.44 million shs	8.65 million shs
IONS Ionis Pharmaceuticals	$43.52 -2.0%	$49.02	$42.08 ▼ $86.74	$7.38B	0.38	2.73 million shs	1.52 million shs
ROIV Roivant Sciences	$36.91 -1.6%	$36.65	$19.30 ▼ $42.50	$27.10B	1.1	6.66 million shs	4.57 million shs
UTHR United Therapeutics	$598.72 +0.9%	$527.10	$430.02 ▼ $609.99	$25.46B	0.49	720,784 shs	502,797 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GMAB Genmab A/S	+1.01%	+30.30%	+59.97%	+97.64%	+97.10%
IONS Ionis Pharmaceuticals	-1.96%	+1.37%	-2.53%	-15.94%	-39.45%
ROIV Roivant Sciences	-1.63%	+1.15%	+0.93%	+8.85%	+96.75%
UTHR United Therapeutics	+0.87%	+1.91%	+10.49%	+15.65%	+31.49%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GMAB Genmab A/S	2.92	Moderate Buy	$53.61	-6.04% Downside
IONS Ionis Pharmaceuticals	2.78	Moderate Buy	$89.48	105.60% Upside
ROIV Roivant Sciences	2.79	Moderate Buy	$46.55	26.11% Upside
UTHR United Therapeutics	2.73	Moderate Buy	$667.07	11.42% Upside

Current Analyst Ratings Breakdown

Latest IONS, GMAB, ROIV, and UTHR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/30/2026	GMAB Genmab A/S	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Equal Weight	$42.00 ➝ $57.00
10/30/2026	GMAB Genmab A/S	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$58.00 ➝ $80.00
10/29/2026	GMAB Genmab A/S	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$45.00 ➝ $67.00
10/29/2026	GMAB Genmab A/S	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$50.00 ➝ $70.00
10/28/2026	ROIV Roivant Sciences	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$46.00 ➝ $56.00
10/28/2026	UTHR United Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$710.00 ➝ $695.00
10/26/2026	UTHR United Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight	$850.00
10/26/2026	GMAB Genmab A/S	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$43.00 ➝ $52.00
10/26/2026	GMAB Genmab A/S	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Neutral ➝ Overweight
10/22/2026	UTHR United Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$708.00 ➝ $697.00
10/22/2026	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy

(Data available from 10/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GMAB Genmab A/S	$4.13B	8.62	$1.63 per share	35.10	$9.10 per share	6.27
IONS Ionis Pharmaceuticals	$944M	7.66	N/A	N/A	$3.02 per share	14.41
ROIV Roivant Sciences	$8.26M	3,227.70	N/A	N/A	$7.35 per share	5.02
UTHR United Therapeutics	$3.18B	8.07	$33.28 per share	17.99	$164.81 per share	3.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GMAB Genmab A/S	$963M	$1.27	44.93	33.76	2.26	19.08%	14.89%	7.73%	11/5/2026 (Estimated)
IONS Ionis Pharmaceuticals	-$381.39M	-$3.46	N/A	N/A	N/A	-64.76%	-111.08%	-17.41%	11/4/2026 (Estimated)
ROIV Roivant Sciences	-$299.77M	-$0.53	N/A	N/A	N/A	-3,534.96%	-22.94%	-21.53%	11/9/2026 (Estimated)
UTHR United Therapeutics	$1.33B	$27.95	21.42	19.43	4.30	41.56%	20.18%	17.98%	11/4/2026 (Estimated)

Latest IONS, GMAB, ROIV, and UTHR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q2 2027	ROIV Roivant Sciences	-$0.3666	N/A	N/A	N/A	$4.15 million	N/A
11/5/2026	Q3 2026	GMAB Genmab A/S	$0.36	N/A	N/A	N/A	$1.20 billion	N/A
11/4/2026	Q3 2026	IONS Ionis Pharmaceuticals	-$1.22	N/A	N/A	N/A	$181.56 million	N/A
11/4/2026	Q3 2026	UTHR United Therapeutics	$6.01	N/A	N/A	N/A	$781.14 million	N/A
8/7/2026	Q1 2027	ROIV Roivant Sciences	-$0.2996	-$0.26	+$0.0396	-$0.26	$2.06 million	$1.44 million
8/6/2026	Q2 2026	GMAB Genmab A/S	$0.37	$0.54	+$0.17	$0.4910	$1.12 billion	$1.16 billion
8/5/2026	Q2 2026	UTHR United Therapeutics	$6.86	$7.27	+$0.41	$7.27	$804.65 million	$783.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GMAB Genmab A/S	0.81	2.46	2.44
IONS Ionis Pharmaceuticals	3.07	7.89	7.73
ROIV Roivant Sciences	N/A	16.72	16.72
UTHR United Therapeutics	N/A	5.73	5.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GMAB Genmab A/S	7.07%
IONS Ionis Pharmaceuticals	93.86%
ROIV Roivant Sciences	64.76%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
GMAB Genmab A/S	1.54%
IONS Ionis Pharmaceuticals	1.81%
ROIV Roivant Sciences	8.80%
UTHR United Therapeutics	8.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GMAB Genmab A/S	3,029	624.06 million	614.45 million	Optionable
IONS Ionis Pharmaceuticals	1,402	166.18 million	163.18 million	Optionable
ROIV Roivant Sciences	721	722.32 million	658.76 million	Optionable
UTHR United Therapeutics	1,400	42.89 million	39.20 million	Optionable

IONS, GMAB, ROIV, and UTHR Headlines

Recent News About These Companies

SGIOY vs. UTHR: Which Stock Is the Better Value Option?

October 30 at 12:41 PM | zacks.com

United Therapeutics (NASDAQ:UTHR) Sets New 52-Week High - Here's What Happened

October 30 at 10:59 AM | marketbeat.com

United Therapeutics (NASDAQ:UTHR) Stock Price Target Cut by JPMorgan Chase & Co.

October 30 at 1:54 AM | americanbankingnews.com

United Therapeutics (UTHR) Cleared To Start Trial For New Pulmonary Hypertension Therapy

October 29 at 6:52 PM | finance.yahoo.com

United Therapeutics (NASDAQ:UTHR) Stock: Insider Martine Rothblatt Sells 9,500 Shares

October 29 at 5:07 PM | marketbeat.com

29,327 United Therapeutics Corporation $UTHR Shares Sold by Simplify Asset Management Inc.

October 29 at 5:52 AM | marketbeat.com

United Therapeutics receives FDA clearance to begin clinical trial of inhaled PAH treatment

October 28 at 7:44 PM | msn.com

United Therapeutics Rising Ahead of Next Earnings Report

October 28 at 7:44 PM | finance.yahoo.com

United Therapeutics (NASDAQ:UTHR) Stock Price Target Lowered at JPMorgan Chase & Co.

October 28 at 3:59 PM | marketbeat.com

Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for

October 28 at 11:07 AM | zacks.com

United Therapeutics Announces FDA Clearance to Proceed with Clinical Trial for Treprostinil-Iloprost SMI in Pulmonary Arterial Hypertension

October 28 at 9:32 AM | marketscreener.comM

United Therapeutics Gets FDA Clearance To Begin Trial Of Inhaled PAH Therapy

October 28 at 9:32 AM | rttnews.com

United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

October 27, 2026 | marketbeat.com

United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Company Stock

October 27, 2026 | insidertrades.com

United Therapeutics (NASDAQ: UTHR) CEO sells shares in prearranged plan

October 27, 2026 | americanbankingnews.com

United Therapeutics Corporation $UTHR Shares Sold by Tower View Wealth Management LLC

October 26, 2026 | marketbeat.com

United Therapeutics Corporation $UTHR Stock Sold by Nisa Investment Advisors LLC

October 24, 2026 | marketbeat.com

United Therapeutics (NASDAQ:UTHR) to Buy Back $2.00 billion in Stock

October 24, 2026 | americanbankingnews.com

Analysts Conflicted on These Healthcare Names: United Therapeutics (UTHR), Elevance Health (ELV) and Abbott Laboratories (ABT)

October 23, 2026 | theglobeandmail.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $5,161,540.00 in Stock

October 23, 2026 | americanbankingnews.com

Share Repurchase Plan Announced by United Therapeutics (NASDAQ:UTHR) Board of Directors

October 22, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IONS, GMAB, ROIV, and UTHR Company Descriptions

Genmab A/S NASDAQ:GMAB

$57.06 +0.57 (+1.01%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$57.08 +0.02 (+0.03%)

As of 10/30/2026 07:34 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Ionis Pharmaceuticals NASDAQ:IONS

$43.52 -0.87 (-1.96%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$43.00 -0.52 (-1.20%)

As of 10/30/2026 07:56 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Roivant Sciences NASDAQ:ROIV

$36.91 -0.61 (-1.63%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$33.94 -2.97 (-8.04%)

As of 10/30/2026 07:55 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

United Therapeutics NASDAQ:UTHR

$598.72 +5.18 (+0.87%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$598.08 -0.64 (-0.11%)

As of 10/30/2026 07:30 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IONS, GMAB, ROIV, and UTHR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IONS, GMAB, ROIV, and UTHR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IONS, GMAB, ROIV, and UTHR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IONS, GMAB, ROIV, and UTHR Company Descriptions

Genmab A/S NASDAQ:GMAB

Ionis Pharmaceuticals NASDAQ:IONS

Roivant Sciences NASDAQ:ROIV

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IONS, GMAB, ROIV, and UTHR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IONS, GMAB, ROIV, and UTHR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IONS, GMAB, ROIV, and UTHR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IONS, GMAB, ROIV, and UTHR Company Descriptions

Genmab A/S NASDAQ:GMAB

Ionis Pharmaceuticals NASDAQ:IONS

Roivant Sciences NASDAQ:ROIV

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools